Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 17467916
Petraschka M, et al. (2007) The absence of endogenous beta-endorphin selectively blocks phosphorylation and desensitization of mu opioid receptors following partial sciatic nerve ligation. Neuroscience 146, 1795-807 17467916
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T180-p - MOR-1 (mouse)
Modsite: VKALDFRtPRNAKIV SwissProt Entrez-Gene
Orthologous residues
MOR‑1 (human): T182‑p, MOR‑1 iso5 (human): T182‑p, MOR‑1 (mouse): T180‑p, MOR‑1 (rat): T180‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  pituitary cancer
Relevant cell lines - cell types - tissues:  'brain, striatum', 293 (epithelial), AtT20 (pituitary cell)
Cellular systems studied:  cell lines, tissue
Species studied:  human, mouse

T370-p - MOR-1 (mouse)
Modsite: sARIRQNtREHPstA SwissProt Entrez-Gene
Orthologous residues
MOR‑1 (human): T372‑p, MOR‑1 iso5 (human): T372‑p, MOR‑1 (mouse): T370‑p, MOR‑1 (rat): T370‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  pituitary cancer
Relevant cell lines - cell types - tissues:  'brain, striatum', 293 (epithelial), AtT20 (pituitary cell)
Cellular systems studied:  cell lines, tissue
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
fentanyl increase
naloxone fentanyl inhibit treatment-induced increase no inhibition in beta-endorphin homozygous null
painful stimulus increase no increase in beta-endorphin homozygous null

S375-p - MOR-1 (mouse)
Modsite: QNtREHPstANtVDR SwissProt Entrez-Gene
Orthologous residues
MOR‑1 (human): S377‑p, MOR‑1 iso5 (human): S377‑p, MOR‑1 (mouse): S375‑p, MOR‑1 (rat): S375‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  pituitary cancer
Relevant cell lines - cell types - tissues:  'brain, striatum', 293 (epithelial), AtT20 (pituitary cell)
Cellular systems studied:  cell lines, tissue
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
fentanyl increase
naloxone fentanyl inhibit treatment-induced increase no inhibition in beta-endorphin homozygous null
painful stimulus increase no increase in beta-endorphin homozygous null

T180-p - MOR-1 (rat)
Modsite: VKALDFRtPRNAKIV SwissProt Entrez-Gene
Orthologous residues
MOR‑1 (human): T182‑p, MOR‑1 iso5 (human): T182‑p, MOR‑1 (mouse): T180‑p, MOR‑1 (rat): T180‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  pituitary cancer
Relevant cell lines - cell types - tissues:  'brain, striatum', 293 (epithelial), AtT20 (pituitary cell)
Cellular systems studied:  cell lines, tissue
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DAMGO no change compared to control

T370-p - MOR-1 (rat)
Modsite: sTRVRQNtREHPsTA SwissProt Entrez-Gene
Orthologous residues
MOR‑1 (human): T372‑p, MOR‑1 iso5 (human): T372‑p, MOR‑1 (mouse): T370‑p, MOR‑1 (rat): T370‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  pituitary cancer
Relevant cell lines - cell types - tissues:  'brain, striatum', 293 (epithelial), AtT20 (pituitary cell)
Cellular systems studied:  cell lines, tissue
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DAMGO increase
naloxone DAMGO inhibit treatment-induced increase

S375-p - MOR-1 (rat)
Modsite: QNtREHPsTANTVDR SwissProt Entrez-Gene
Orthologous residues
MOR‑1 (human): S377‑p, MOR‑1 iso5 (human): S377‑p, MOR‑1 (mouse): S375‑p, MOR‑1 (rat): S375‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  pituitary cancer
Relevant cell lines - cell types - tissues:  'brain, striatum', 293 (epithelial), AtT20 (pituitary cell)
Cellular systems studied:  cell lines, tissue
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DAMGO increase
naloxone DAMGO inhibit treatment-induced increase